ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
종목 코드 NDRA
회사 이름ENDRA Life Sciences Inc
상장일Jun 28, 2017
CEOTokman (Alexander Y)
직원 수21
유형Ordinary Share
회계 연도 종료Jun 28
주소3600 Green Ct Ste 350
도시ANN ARBOR
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호48105
전화17343350468
웹사이트https://www.endrainc.com/
종목 코드 NDRA
상장일Jun 28, 2017
CEOTokman (Alexander Y)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음